Therapeutic for Acute Lung Injury

OCR Number: OCR 7222

Description:

Low-dose of ChemoRx Prevents/Treats Acute Lung Injury

- **About the indications/in vivo models**
  - ALI/ARDS LPS injury model
  - Acute-induced lung injury
  - Clinical utility: Emergency Department, ICU's

- **About the target/specificity**
  - Well-characterized enzyme & pathway
  - Target validated by KO
  - OCR7222 acts on ALI in a target-specific mechanism

- **Mechanism**
  - Biology well-characterized
  - Surprising result: cell-specific biological response is favorable, unlike tissue-wide induction of pathway.

- **About the agent**
  - Oral small molecule
  - Approved for oncology indications via oral delivery
  - OCR7222 composition is generic or comes off patent 2021-23

- **Novelty**
  - New indication
  - Ultra-low effective dose 1/40° of chemotherapeutic dose
  - Novel route of delivery: inhalation

- **OCR7222 IP Status:**
  - Unpublished
  - Provisional patent filed
  - Both available under CDA

**PI:** Dianqing Wu

**Licensing Contact:** David Lewin
david.lewin@yale.edu